A tolerizing mRNA vaccine prevents autoimmune disease in mice.
Vaccines based on mRNA have dominated the headlines during the COVID-19 pandemic owing to their high efficacy and unprecedented speed of development and manufacture. In a recent paper in Science, Ugur Sahin, who led the development of a COVID-19 mRNA vaccine1, and coauthors have now harnessed this vaccine technology to suppress, rather than prime, antigen-specific immune responses2. Working with mouse models of multiple sclerosis, they show that immunization with a modified mRNA encoding a self antigen and delivered in a non-inflammatory lipoplex carrier leads to a dampening of autoimmunity through the activation of antigen-specific regulatory T cells (Fig. 1). Although further research is needed to assess the clinical potential of the strategy, a successful tolerizing vaccination approach could transform the treatment of autoimmune diseases, allergies and allogeneic transplantation.
mRNA vaccines consist of antigen-encoding RNA encapsulated in lipid nanoparticles3. Sahin and colleagues initially developed mRNA vaccines with the aim of stimulating immunity against tumors4. In those studies, the net negative charge of the mRNA–lipid nanoparticle resulted in their macropinocytosis by splenic dendritic cells, activation of Toll-like receptor 7 (TLR7), production of interferon-α, and triggering of antigen-specific immunity4. In parallel, Kariko and colleagues developed a modification of mRNA-based vaccines that incorporated 1-methylpseudouridine (m1Ψ), a naturally occurring component of eukaryotic 18S ribosomal RNA, in place of uridine, finding that m1Ψ mRNA had a higher translational capacity and lower innate immune activation because it did not stimulate TLR75,6.
Reasoning that an anti-inflammatory, m1Ψ-based mRNA vaccine could be advantageous for disease contexts where suppression of immunity was desired, in the new study Sahin and colleagues2 investigated whether m1Ψ mRNA vaccination could prevent autoimmunity. The authors focused on a mouse model of multiple sclerosis, experimental autoimmune encephalomyelitis (EAE), that can be triggered by immunization with a myelin oligodendrocyte glycoprotein peptide (MOG35–55) and strong adjuvant. MOG is an autoantigen associated with multiple sclerosis; in EAE, MOG-specific T cells drive disease, causing progressive nerve damage. In the absence of adjuvant, administration of MOG m1Ψ mRNA in healthy mice induced significantly higher MOG-specific T cell proliferation than did administration of MOG uridine mRNA, but the m1Ψ mRNA-stimulated T cells expressed high levels of exhaustion markers and minimal amounts of inflammatory cytokines. Importantly, the m1Ψ mRNA formulation also stimulated proliferation of suppressive, MOG-specific FoxP3+ regulatory T (Treg) cells.
After mice are immunized with MOG peptide and an adjuvant, clinical signs of disease appear in 10–15 days. To test whether m1Ψ mRNA could prevent disease, the authors first injected the MOG peptide and adjuvant and then administered m1Ψ mRNA encoding MOG or an irrelevant peptide 7 and 10 days later, before symptoms developed. Mice that received MOG m1Ψ mRNA were indeed protected from developing EAE, whereas mice treated with m1Ψ mRNA encoding an irrelevant peptide developed disease similarly to saline-treated mice. When the tolerizing treatment was delayed to the time of early disease onset (at around day 10, when partial paralysis is detected), only MOG m1Ψ mRNA prevented disease progression. Similar results were found in a relapsing–remitting EAE model induced by a proteolipid protein (PLP139–151) peptide in SJL mice.
Analysis of the cellular immune response in MOG m1Ψ mRNA-treated mice revealed less T cell infiltration and reduced demyelination in the brain and spinal cord. Furthermore, the spleens of protected mice contained MOG-specific T cells expressing low levels of activation markers, high levels of co-inhibitory molecules, and higher numbers of activated Treg cells. The efficacy of the MOG m1Ψ mRNA treatment was significantly reduced by antibodies blocking CTLA-4 or PD-1, possibly as a result of interference with mechanisms of action in Treg cells or by enhancement of T cell effector functions, respectively. Taken together, these data suggest that although m1Ψ mRNA vaccination promotes the expansion of Treg cells, it does not delete pre-existing autoreactive T cells. Notably, m1Ψ mRNA administration did not induce MOG-specific autoantibodies, which is a potential risk of therapies involving administration of disease-relevant autoantigens.
Because multiple sclerosis is driven by several autoantigens, successful immune tolerizing interventions in patients might require Treg cells that not only suppress cognate autoreactive T cells but also mediate bystander suppression of autoreactive T cells bearing other antigen specificities. To test whether m1Ψ mRNA-expanded Treg cells were capable of bystander suppression, the authors induced EAE with the PLP peptide and then treated them with MOG m1Ψ mRNA or PLP m1Ψ mRNA; both treatments led to similar reductions in symptoms, suggesting that Treg cells activated by MOG m1Ψ mRNA were capable of bystander suppression. Moreover, in an EAE model triggered with five autoantigens, vaccination with m1Ψ mRNA encoding a single peptide or a mixture of four autoantigens provided protection, with a trend toward better protection with the latter strategy. Thus, more work is required to understand the role of antigen-specific versus bystander mechanisms of tolerance induction.
A potential safety concern of m1Ψ mRNA vaccination is the possibility of generalized immune suppression caused by long-lasting tolerogenic effects on the dendritic cells that take up RNA lipoplexes. To address this, Sahin and colleagues showed that prior treatment with m1Ψ mRNA did not prevent dendritic cells from upregulating activation markers and producing interferon-α when subsequently challenged with uridine mRNA in vivo, suggesting that the dendritic cells remain fully functional after m1Ψ internalization. Moreover, treatment with MOG m1Ψ mRNA did not hamper the development of T cell immunity to model antigens delivered by uridine mRNA vaccination. Thus, dendritic cells exposed to m1Ψ mRNA are not refractory to activation, indicating that the anti-inflammatory effect of m1Ψ mRNA vaccination is remarkably specific.
Sahin and colleagues have clearly demonstrated the potential of RNA lipoplex vaccines to deliver a non-inflammatory form of an mRNA vaccine encoding a self antigen to prevent and limit autoimmune disease in mice. It is noteworthy that m1Ψ-containing mRNA is also used for the COVID-19 mRNA vaccine1,7, indicating that the pro- versus anti-inflammatory nature of m1Ψ mRNA vaccines can be modulated depending on the specific antigen and specific encapsulating lipid formulation. In the case of the BNT162b2 vaccine for COVID-19, the antigen is a foreign protein formulated in an immunostimulatory lipid nanoparticle8. In the present study, the antigen is a self protein delivered in a non-immunogenic lipoplex formulation, and an extra mRNA purification step removes any residual immunostimulatory molecules2. This method allows antigen presentation in the absence of inflammation and co-stimulation, preferential expansion of pre-existing Treg cells, and possibly also their de novo development.
The notion that vaccines based on nucleic acids could be effective in resetting immune responses in multiple sclerosis is not new: 15 years ago, vaccination with DNA encoding myelin basic protein was found to induce favorable trends on brain magnetic resonance imaging and beneficial antigen-specific immune effects9. This is also not the first time that the delivery of autoantigens in an anti-inflammatory format has been explored as a method to induce tolerance. Previous approaches have included peptide or protein delivery in anti-inflammatory formats using methods such as oral, nasal or subcutaneous administration, or delivery on carriers such as cells or major histocompatibility complex molecules10. However, the success of these DNA- and protein-based concepts in the clinic has been mixed, with generally underwhelming results so far9,10. The major advantages of the RNA lipoplex antigen delivery system are that it is easily adaptable to any protein antigen (or indeed combination of antigens) and feasible and cost-effective at large scales3. This means the approach would be applicable in large numbers of people, and might also include repeat dosing.
Before m1Ψ mRNA vaccination to treat autoimmune diseases can be translated to humans, key questions related to defining optimal disease-specific autoantigen targets and to the longevity and specificity of the effect must be answered. By design, animal models of EAE are typically driven by one predominant, disease-causing autoantigen, whereas multiple sclerosis is driven by a complex polyclonal T cell repertoire10,11. More work will be needed to fully understand the capacity for, and breadth of, bystander suppression. The current report did not include formal demonstration of tolerance by a later rechallenge with the autoantigen in a non-tolerogenic format, or by the adoptive transfer of Treg cells to naive mice (for demonstrating ‘dominant’ tolerance). Autoimmune diseases in humans are thought to involve continuous exposure to autoantigens, possibly coincident with inflammatory stimuli; therefore, it will be important to establish the length of the immunoregulatory effect and whether repeat vaccination is safe or advantageous. Finally, the fact that similar approaches can be used to stimulate immune responses1 underlines the need to fully understand the mechanisms that control the pro-versus anti-inflammatory nature of mRNA vaccines to eliminate the risk of deleterious immune stimulation. Nevertheless, the simplicity and remarkable potential of m1Ψ mRNA demonstrated by Sahin and colleagues is very encouraging.
Polack, F. P. et al. N. Engl. J. Med. 383, 2603–2615 (2020).
Krienke, C. et al. Science 371, 145–153 (2021).
Sahin, U., Karikó, K. & Türeci, Ö. Nat. Rev. Drug Discov. 13, 759–780 (2014).
Kranz, L. M. et al. Nature 534, 396–401 (2016).
Karikó, K., Buckstein, M., Ni, H. & Weissman, D. Immunity 23, 165–175 (2005).
Karikó, K. et al. Mol. Ther. 16, 1833–1840 (2008).
Walsh, E. E. et al. N. Engl. J. Med. 383, 2439–2450 (2020).
FDA. Pfizer-BioNTech COVID-19 vaccine EUA Letter of Authorization reissued 02252021. https://www.fda.gov/media/144412/download (2020).
Bar-Or, A. et al. Arch. Neurol. 64, 1407–1415 (2007).
Serra, P. & Santamaria, P. Nat. Biotechnol. 37, 238–251 (2019).
Hohlfeld, R., Dornmair, K., Meinl, E. & Wekerle, H. Lancet Neurol. 15, 198–209 (2016).
The authors declare no competing interests.
About this article
Cite this article
Wardell, C.M., Levings, M.K. mRNA vaccines take on immune tolerance. Nat Biotechnol 39, 419–421 (2021). https://doi.org/10.1038/s41587-021-00880-0